
Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Panelists discuss how lifestyle interventions, including diet, physical activity, and smoking cessation, complement pharmacotherapy in the management of dyslipidemia, and explore unmet needs in cardiovascular risk reduction, highlighting the role of emerging therapies such as bempedoic acid, inclisiran, and gene editing technologies.
Navigating Lifestyle and Pharmacotherapy Interventions in Dyslipidemia Management






